Latest News
Inhibrx reports positive interim Phase 2 data for INBRX-106 in first-line head and neck cancer
11 May 2026 - Biopharmaceutical company Inhibrx Biosciences Inc (Nasdaq: INBX) on Monday reported positive interim results from the Phase 2 portion of its HexAgon study evaluating INBRX-106 in combination with pembrolizumab for first-line treatment o...
Vector Science & Therapeutics secures three-year manufacturing partnership with MPP Group to expand peptide pipeline
11 May 2026 - Medical technology company Vector Science & Therapeutics (TSXV: PAIN) announced on Monday that it has entered a three-year development and manufacturing agreement with MPP Group LLC to support the production of pharmaceutical-grade ...
Anixa Biosciences reports extended survival signals in Phase 1 ovarian cancer CAR-T trial
11 May 2026 - Biotechnology company Anixa Biosciences Inc (NASDAQ: ANIX) on Monday reported updated positive survival observations from its ongoing Phase 1 trial of liraltagene autoleucel (lira-cel), an investigational CAR-T therapy for recurrent ova...
Oncopeptides plans EMA filing to broaden Pepaxti indication
11 May 2026 - Oncopeptides AB (STO:ONCO), a Swedish biotech company focused on difficult-to-treat cancers, said on Monday that it intends to submit a Type II variation application to the European Medicines Agency (EMA) to expand the indication for Pe...
GSK partners with SBP Group to accelerate China launch of bepirovirsen
11 May 2026 - Biopharmaceutical company GSK plc (LSE/NYSE: GSK) announced on Monday that it has entered an exclusive strategic collaboration with Sino Biopharmaceutical Limited through subsidiary Chia Tai Tianqing Pharmaceutical Group Co, Ltd to supp...